Expertise in
1
conditions

Dr. Nathan Segall

Allergy and Immunology
Nathan Segall M.D. P.C.
980 Johnson Ferry Rd Ste 1080, 
Atlanta, GA 
Expertise in
1
conditions
Nathan Segall M.D. P.C.
980 Johnson Ferry Rd Ste 1080, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nathan Segall is an Allergy and Immunologist in Atlanta, Georgia. Dr. Segall is highly rated in 1 condition, according to our data. His top areas of expertise are Allergic Rhinitis, Grass Allergy, and Sinusitis.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Allergy and Immunology
Licenses
Internal Medicine in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO

Locations

Nathan Segall M.D. P.C.
980 Johnson Ferry Rd Ste 1080, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Enrollment Status: Completed
Publish Date: May 17, 2023
Intervention Type: Drug
Study Drug: PUL-042 Inhalation Solution
Study Phase: Phase 2
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Phase: Phase 1
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
CSD190601: A Study to Determine Subject Puffing Patterns of Electronic Nicotine Delivery Systems in an Ambulatory Setting
CSD190601: A Study to Determine Subject Puffing Patterns of Electronic Nicotine Delivery Systems in an Ambulatory Setting
Enrollment Status: Completed
Publish Date: January 20, 2022
Intervention Type: Other
Study Phase: Not Applicable
CSD170201: A Crossover Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products
CSD170201: A Crossover Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products
Enrollment Status: Completed
Publish Date: April 10, 2018
Intervention Type: Other
Study Phase: Not Applicable
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: March 13, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
CSD170202: A Crossover Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products
CSD170202: A Crossover Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products
Enrollment Status: Completed
Publish Date: September 08, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 8 Less Clinical Trials

17 Total Publications

Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trial.
Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: August 30, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Paul Rabinowitz
Allergy and Immunology
Expertise in
19
conditions
Dr. Paul Rabinowitz
Allergy and Immunology

Allergy And Asthma Consultants PC

5555 Peachtree Dunwoody Rd Ste 325, 
Atlanta, GA 
 (28.6 miles away)
770-889-8636
Languages Spoken:
English
See accepted insurances

Paul Rabinowitz is an Allergy and Immunologist in Atlanta, Georgia. Dr. Rabinowitz is highly rated in 19 conditions, according to our data. His top areas of expertise are Hives, Ozena, Nonallergic Rhinopathy, and Allergic Rhinitis.

Expertise in
18
conditions
Dr. Stanley Fineman
Allergy and Immunology
Expertise in
18
conditions
Dr. Stanley Fineman
Allergy and Immunology

Atlanta Allergy & Asthma

1519 Johnson Ferry Rd Ste 200, 
Marietta, GA 
 (37.3 miles away)
770-973-5578
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stanley Fineman is an Allergy and Immunologist in Marietta, Georgia. Dr. Fineman is highly rated in 18 conditions, according to our data. His top areas of expertise are Allergic Rhinitis, Sinusitis, Grass Allergy, and Asthma.

Frances E. Lee
Expertise in
5
conditions
Dr. Frances E. Lee
Allergy and Immunology
Expertise in
5
conditions
Dr. Frances E. Lee
Allergy and Immunology

Emory Clinic - Pulmonology At Executive Park

1605 Chantilly Drive Northeast, Ste301, 
Atlanta, GA 
 (22.9 miles away)
404-778-3261
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients

Frances Lee is an Allergy and Immunologist in Atlanta, Georgia. Dr. Lee is highly rated in 5 conditions, according to our data. Her top areas of expertise are Allergic Bronchopulmonary Aspergillosis, Aspergillosis, Asthma, and Pulmonary Aspergilloma. Dr. Lee is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Segall's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile